Abstract：
This systematic review aims to evaluate the efficacy and safety of Pyridoxine compared to Dopaminergic agonists (cabergoline and bromocriptine) in post-partum lactation inhibition. Cochrane Central, PubMed/MEDLINE, Cochrane Central, ScienceDirect, ClinicalTrials.gov, Web of Science, CINAHL and Google Scholar, covering the period from inception to November 2023. Additionally, the bibliographies of included articles and previous meta-analyses were screened for any relevant articles. The systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. The outcomes of interest encompassed inhibition of lactation, breast pain/tenderness, breast engorgement, milk secretion, fever, mastitis, prolactin level and adverse events related to pyridoxine, cabergoline and bromocriptine. Methodological quality assessment was conducted using the Cochrane risk of bias assessment tool for rigorous evaluation. Three clinical trials assessed the effectiveness of pyridoxine and dopaminergic agents (cabergoline and bromocriptine) for lactation inhibition. It was assessed by using different assessment methods such as a scale for milk secretion, serum prolactin levels, and questionnaires for assessing breast engorgement, breast pain, and milk leakage. On the global assessment of the therapeutic efficacy of dopaminergic agents, it was found that there was significant inhibition of lactation as compared to pyridoxine (p < 0.001). In conclusion, this systematic review contributes significant insights into lactation inhibition interventions. Dopaminergic agonists, specifically cabergoline and bromocriptine, stand out as more effective and tolerable choices compared to Pyridoxine. These findings provide a foundation for informed clinical decisions and underscore the need for careful consideration of lactation inhibition strategies in diverse clinical contexts.
摘要：
本系统评价旨在评估吡哆醇与多巴胺能激动剂（卡麦角林和溴隐亭）在产后泌乳抑制中的疗效和安全性。CochraneCentral,PubMed/MEDLINE,CochraneCentral,ScienceDirect,ClinicalTrials.gov,WebofScience,CINAHL和谷歌学者，涵盖从成立到2023年11月的时期。此外,对纳入的文章的参考书目和以前的荟萃分析进行了筛选,以查找相关文章.系统评价是根据《Cochrane干预措施系统评价手册》进行的。感兴趣的结果包括抑制泌乳，乳房疼痛/压痛，乳房充血,乳汁分泌，发烧,乳腺炎,与吡哆醇相关的催乳素水平和不良事件，卡麦角林和溴隐亭。方法学质量评估采用Cochrane偏倚风险评估工具进行严格评估。三项临床试验评估了吡哆醇和多巴胺能药物（卡麦角林和溴隐亭）抑制泌乳的有效性。通过使用不同的评估方法进行评估，例如乳汁分泌量表，血清催乳素水平，和评估乳房充盈的问卷，乳房疼痛,和牛奶泄漏。关于多巴胺能药物治疗效果的全球评估，发现与吡哆醇相比，泌乳有明显的抑制作用（p<0.001）。总之,本系统综述为哺乳抑制干预提供了重要见解.多巴胺能激动剂，特别是卡麦角林和溴隐亭，与吡哆醇相比，它是更有效和更可耐受的选择。这些发现为明智的临床决策提供了基础，并强调了在不同临床环境中仔细考虑泌乳抑制策略的必要性。
